Why Is Ogsiveo So Hard to Find? [Explained for 2026]

If you or a loved one has been prescribed Ogsiveo (nirogacestat) for a desmoid tumor, you may have quickly discovered that it doesn't work like most medications. You can't walk up to a CVS or Walgreens counter and pick it up. It's not on the shelves at your local grocery store pharmacy. And your usual insurance card may not automatically cover it without a fight.

Here's the short answer: Ogsiveo is a specialty medication for a rare disease, and that classification changes everything about how you obtain it. This guide explains exactly why Ogsiveo is challenging to access, what the specialty pharmacy process looks like, and how patients are navigating this system in 2026.

What Makes Ogsiveo a 'Specialty' Drug?

Ogsiveo (nirogacestat) received FDA approval on November 27, 2023, making it the first and only approved treatment for adults with progressing desmoid tumors. Desmoid tumors are rare, non-cancerous but locally aggressive soft tissue tumors — and the patient population that needs this drug is small.

Because of its orphan drug status and the complexity of the therapy, Ogsiveo is classified as a specialty medication. Specialty drugs are typically:

Distributed exclusively through a network of specialty pharmacies

Expensive (often $10,000 or more per month)

Subject to additional dispensing and monitoring requirements

Accompanied by patient support programs from the manufacturer

Ogsiveo checks all of these boxes. Its list price runs approximately $25,000–$30,000 per month, and it is dispensed only through specialty pharmacies that are part of the SpringWorks CareConnections network.

Is Ogsiveo in a Drug Shortage?

As of 2026, Ogsiveo is not listed on the FDA Drug Shortage Database. The medication itself is commercially available. However, patients still face significant access challenges — and those challenges can feel like a shortage even when the drug is technically in stock somewhere.

One important note: in early 2025, the 50 mg tablet of Ogsiveo was discontinued. SpringWorks Therapeutics reformulated the product into 100 mg and 150 mg tablets for easier dosing. Patients who were previously stabilized on the 50 mg dose had to work with their care team to transition. While this wasn't a supply shortage, it did create temporary confusion and access disruption for some patients.

Why Can't I Fill Ogsiveo at a Regular Pharmacy?

Retail pharmacies like CVS, Walgreens, and Rite Aid are not equipped to dispense Ogsiveo. The reasons are both clinical and commercial:

Limited demand: Desmoid tumors are rare. Most retail pharmacies would rarely if ever dispense this medication, making it impractical to stock.

Specialty pharmacy contracts: Manufacturers of rare-disease drugs typically restrict distribution to a network of specialty pharmacies that provide additional clinical support services.

Insurance routing: Your insurance plan will often mandate which specialty pharmacy you can use for a given drug, narrowing your choices further.

This means that even if you drive to a well-stocked pharmacy, they simply will not have Ogsiveo on hand — and they cannot order it for you.

The Prior Authorization Hurdle

Even after you've identified the right specialty pharmacy, you'll likely need to clear a prior authorization (PA) before your insurance will pay. The PA process requires your oncologist to submit documentation proving that:

You are 18 years or older

You have a confirmed diagnosis of desmoid tumor (via biopsy)

Your tumor has progressed within the last 12 months or is causing significant symptoms

Systemic therapy is appropriate for your case

PA denials are common on the first attempt, especially if paperwork is incomplete. The good news: SpringWorks CareConnections (1-844-CARES-55) has nurse advocates who can help you and your oncologist navigate the process. If your coverage is delayed, a Quick Start or Gap Coverage program may provide your medication at no cost while the insurance decision is pending.

How Patients Are Finding Ogsiveo in 2026

The most successful patients start with their oncologist's office. A sarcoma or oncology practice that routinely prescribes Ogsiveo will have established relationships with specialty pharmacies and a clear PA process. Here's what the typical access path looks like:

Your oncologist submits the prescription to the SpringWorks-preferred specialty pharmacy.

The specialty pharmacy contacts you (often from an unfamiliar number) to gather information and verify benefits.

Insurance prior authorization is submitted and processed (this can take days to weeks).

Financial assistance is confirmed — many patients pay $0 with the commercial copay program.

Medication is shipped to your home or a nearby pickup location.

If you're having trouble navigating this process — or if you're not being seen at a major sarcoma center — a service like medfinder can help you locate which pharmacies in your area can fill your prescription, saving you time on the phone.

What If My Specialty Pharmacy Doesn't Have It?

Although Ogsiveo is not in a nationwide shortage, individual specialty pharmacies can run out of stock or face delays. If your assigned pharmacy says there's a delay:

Ask your oncologist's office if they can transfer the prescription to another in-network specialty pharmacy.

Contact SpringWorks CareConnections at 1-844-CARES-55 — they can often direct you to an alternative pharmacy that has supply.

Ask about the Quick Start or Gap Coverage bridge programs if delays are affecting your treatment continuity.

The Bottom Line

Ogsiveo isn't hard to find because of a shortage — it's hard to find because it's a specialty drug that operates outside the normal pharmacy ecosystem. The key is knowing how to navigate specialty pharmacy networks, prior authorizations, and patient assistance programs. For more practical tips, check out our guide on how to find Ogsiveo in stock near you.